Global Women Health Therapeutics Market 2019-2025
|発行||Orion Market Research Pvt Ltd||商品コード||486703|
|婦人科系疾患治療薬の世界市場の調査・分析 Global Women Health Therapeutics Market 2019-2025|
|出版日: 2019年12月30日||ページ情報: 英文||
Global Women Health Therapeutics Market Size, Share & Trends Analysis Report by Type (Infection, Pregnancy, and Oncology) and by End-User (Hospitals and Clinics and Ambulatory Centers) and Forecast 2019-2025
Global women health therapeutics market is anticipated to exhibit a significant growth at a CAGR 4.4% during the forecast period. In the healthcare industry, women health therapeutics market is a constantly growing segment as every woman has to deal with some kind of gynecological disorder at some point in their lifetime. While most of the gynecological diseases can be cured with proper treatment; however, in certain cases, they can prove fatal unless diagnosed at the right time. In present times, women health therapeutics market has a notable pipeline of promising molecules at several stages of clinical development. Some of such molecules are AZD4901, romosozumab (AMG785), abaloparatide, elagolix, ASP1707, vaginorm, and teriparatide. However, the patent expiry of drugs is expected to pose challenges in the growth of the global women health therapeutics market. Furthermore, supportive government initiatives coupled with improving healthcare infrastructure in emerging economies are projected to create significant growth opportunities for the global market.
The global women health therapeutics market is segmented on the basis of type and end-user. Based on type, the market is segmented into an infection, pregnancy, and oncology. Based on end-user, the market is bifurcated into hospitals and clinics and ambulatory centers. Infection is accounted for the substantial market share and is expected to maintain its presence in the market during the forecast period. This is due to the high incidence of infectious diseases, increasing drug approvals, and the availability of diagnostics tests and treatments.
Global women health therapeutics market can be segmented geographically into North America, Europe, Asia-Pacific, and Rest of the World. Amongst them, North America and Europe held a significant share in the global market, owing to the growing focus towards women health and increasing elderly population. The high prevalence of chronic disorders such as breast cancer in the US further propels the growth of the women health therapeutics market in North America. The rapidly emerging economies of Asia-Pacific are projected to witness the considerable growth rate in the global market during the forecast period. The growth is backed by the growing awareness about the diversified treatment options for women health issues coupled with the rising prevalence of urological disorders within the region.
The key players of women health therapeutics market include Novartis AG, Abbott Laboratories, Inc., Pfizer Inc., Eli Lilly and Co., Bayer AG, Merck KGaA, Novo Nordisk A/S, and F. Hoffmann-La Roche Ltd. Product launch, merger and acquisition, and partnerships are some of the key strategies adopted by the market players and sustain and capture the major market share in the women health therapeutics market.
The market study of the global women health therapeutics market is incorporated by extensive primary and secondary research conducted by the research team. Secondary research has been conducted to refine the available data to breakdown the market in various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. Our team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior and macro-economic factors. Numbers extracted from secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables our analyst to derive the closest possible figures without any major deviations in the actual number. Our analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings authenticity in our reports.
Secondary Sources Include
The report is intended for pharmaceutical companies for overall market analysis and competitive analysis. The report provides an in-depth analysis of market size, intended quality of the service preferred by consumers. The report will serve as a source for a 360-degree analysis of the market thoroughly integrating different models.
The Report Covers